GO:0002430 complement receptor mediated signaling pathway

The complement system is a cornerstone of innate immunity, and its effector functions are largely mediated through specific receptors that recognize complement proteins and their activation fragments. GO:0002430, complement receptor mediated signaling pathway, defines the series of molecular signals generated as a consequence of a component of the complement pathway binding to a complement receptor [1,4]. This process converts extracellular complement deposition into intracellular signals that shape immune cell behavior, vascular function, and tissue homeostasis. The pathway is initiated by ligands such as C5a, C3a, and C3b, which engage G-protein-coupled receptors (GPCRs) like C5aR1, C5aR2, and C3aR, or other receptors such as CRIg [1,3,4]. These interactions trigger downstream cascades involving G proteins, beta-arrestins, kinases, and calcium mobilization, ultimately modulating chemotaxis, cytokine release, and cellular metabolism [1,7]. Researchers study GO:0002430 because it sits at the intersection of immunology, vascular biology, and cancer biology. For example, C3 adapts the cerebrospinal fluid to support leptomeningeal metastasis, a process dependent on complement receptor signaling in the tumor microenvironment. Endothelial C3aR mediates blood-brain barrier permeability during aging, linking complement receptor signaling to neurovascular dysfunction. In lupus nephritis, the C5a-C5aR1 axis controls mitochondrial fission and podocyte injury, highlighting a role in kidney pathology. Furthermore, C5a/C5aR pathway blocking has been shown to promote cancer therapy by inhibiting cuproptosis resistance, revealing a metabolic dimension of this pathway. These findings underscore the importance of precise genetic models to dissect the contribution of individual receptors and signaling nodes. The pathway is not monolithic; biased signaling at C5aR1 allows different ligands to preferentially activate distinct downstream effectors, which has therapeutic implications. Additionally, a CD4+ T cell-intrinsic C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 cell contraction, demonstrating cell-type-specific functions. In the retina, C3/C3aR signaling inhibition ameliorates damage in experimental retinal vein occlusion, further expanding the disease relevance. Thus, GO:0002430 encompasses a versatile signaling module that is critical for both protective immunity and pathological inflammation.

GO:0002430, complement receptor mediated signaling pathway, is defined as the series of molecular signals generated as a consequence of a component of the complement pathway binding to a complement receptor. Such components include both whole complement proteins and fragments of complement proteins generated through the activity of the complement pathway. This biological process transforms the recognition of complement ligands into intracellular signaling events that alter cell behavior, including changes in gene expression, cytoskeletal dynamics, and metabolism.

GO:0002430 is critically important because it translates complement activation into cellular responses that can be protective or pathogenic. Dysregulation of this pathway is implicated in a wide range of diseases, including cancer metastasis, age-related vascular inflammation, autoimmune conditions like lupus nephritis, and retinal vascular disorders [2,4,6,8]. Understanding the precise molecular mechanisms and identifying the key genes involved is essential for developing targeted therapies that modulate complement receptor signaling without compromising host defense.

The following genes encode the major receptors, ligands, and downstream effectors that constitute or regulate the complement receptor mediated signaling pathway.

The complement receptor mediated signaling pathway is tightly regulated at multiple levels. Receptor desensitization and internalization are controlled by phosphorylation and beta-arrestin recruitment, which terminate G protein signaling and initiate alternative cascades. Negative regulators such as C5aR2 can act as decoy receptors or modulate signaling without G protein activation. Additionally, the availability of ligands is regulated by complement regulatory proteins (e.g., CD55, CD46) and proteases that generate or degrade C3a and C5a. In disease states, sustained activation can lead to pathological outcomes, as seen in lupus nephritis where C5a-C5aR1 signaling drives mitochondrial fission. Therapeutic strategies often aim to block ligand-receptor interactions or inhibit downstream effectors to restore homeostasis [5,8].

Complement component C3 adapts the cerebrospinal fluid to support leptomeningeal metastasis, a devastating complication of cancer. This process depends on complement receptor signaling in the tumor microenvironment, highlighting GO:0002430 as a driver of metastatic niche formation. Additionally, blocking the C5a/C5aR pathway has been shown to promote copper sulfide (CuS)-mediated cancer therapy by inhibiting cuproptosis resistance, linking complement receptor signaling to metabolic regulation of cell death. These findings suggest that targeting this pathway could enhance the efficacy of existing cancer treatments.

In lupus nephritis, the C5a-C5aR1 axis controls mitochondrial fission to promote podocyte injury. Activation of C5aR1 on podocytes leads to Drp1-mediated mitochondrial fragmentation, contributing to proteinuria and kidney damage. This implicates GO:0002430 in the pathogenesis of autoimmune kidney disease and suggests that C5aR1 blockade or inhibition of mitochondrial fission could be therapeutic.

Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. C3aR activation on endothelial cells triggers inflammatory signaling that compromises barrier integrity, potentially contributing to age-related cognitive decline and neurovascular dysfunction. This positions GO:0002430 as a key player in aging-related pathologies.

Complement C3/C3aR signaling pathway inhibition ameliorates retinal damage in experimental retinal vein occlusion. This indicates that complement receptor mediated signaling contributes to retinal ischemia-reperfusion injury and that targeting C3aR may be beneficial in retinal vascular disorders.

CRISPR-Cas9 mediated knockout of complement receptors (e.g., C5AR1, C3AR1, CRIG) in cell lines and animal models is a powerful approach to determine their causal roles in signaling and disease. Knock-in of point mutations, such as those disrupting beta-arrestin binding sites in C5aR1, allows dissection of biased signaling in vivo. These models can be combined with disease challenges, such as lupus nephritis induction or cancer metastasis assays, to evaluate phenotypic outcomes [2,6].

Measuring second messengers (cAMP, IP3, calcium), kinase activation (phospho-ERK, phospho-Akt), and beta-arrestin recruitment is essential to characterize pathway activation. For example, calcium mobilization assays and BRET-based beta-arrestin recruitment assays can quantify biased signaling at C5aR1. Western blotting for downstream effectors like Drp1 phosphorylation can reveal mitochondrial dynamics changes in podocytes.

RNA-seq and proteomics can identify global changes in gene expression and protein phosphorylation following complement receptor activation. This is particularly useful for understanding how C5aR2 signaling alters T cell transcriptional programs, such as the prostacyclin-IL-1R2 axis. Phosphoproteomics can uncover novel kinase substrates downstream of C5aR1.

Live-cell imaging of calcium flux, cytoskeletal dynamics, and receptor internalization provides spatiotemporal insights. Flow cytometry can assess immune cell activation markers and chemotaxis. In vivo imaging of blood-brain barrier permeability in C3aR knockout mice can directly visualize vascular leakage.

Researchers studying complement receptor mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in a specific disease or cellular process. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and accelerating therapeutic development.

GO:0002430, complement receptor mediated signaling pathway, is a fundamental biological process that translates complement activation into diverse cellular responses. Its involvement in cancer, autoimmune diseases, and age-related vascular pathologies underscores its importance as a therapeutic target. Advances in CRISPR-based genetic models and high-throughput screening are enabling precise dissection of the pathway's components and their causal roles in disease. EDITGENE's comprehensive services support researchers in generating the necessary tools to accelerate discovery in this field.